229株阴沟肠杆菌的标本分布及耐药性分析

目的 了解阴沟肠杆菌在医院感染的标本分布和耐药情况,为临床合理选择和应用抗生素提供依据.方法 采用VITEK 60全自动微生物分析仪和配套的GNI、GNS-143、GNI-448,对229株阴沟肠杆菌进行分离鉴定和药敏试验,药敏结果使用WHONET 5.5软件进行分析.结果 从2007年1月至2011年9月共分离到阴沟肠杆菌229株,59.0％来自于呼吸道标本,其次是尿液占13.5％,再次为创面分泌物/脓液占12.7％.阴沟肠杆菌对美洛培南、亚胺培南和头孢哌酮/舒巴坦的耐药率分别为0.0％、0.4％和2.5％,对氨苄西林、头孢唑啉、头孢西丁的耐药率分别为98.7％、96.9％、97.5％.结论 阴沟肠杆菌耐药机制复杂,对抗生素具有多重耐药性,临床应合理使用抗菌药物,以减少阴沟肠杆菌耐药性的产生和在院内扩散.

Distribution and drug resistance of 229 strains of Enterobacter cloacae

Objective To learn the specimen distribution and drug resistance of Enterobacter cloacae in the hospital,and provide basis for,reasonable choice for antibiotics.Methods VITEK 60 automatic micro-analyzer and the supporting GNI,GNS-143 and GNI-448 were used for the isolation,identification and susceptibility test of the 229 strains of Enterobacter cloacae.Sensitivity results were analyzed by using WHONET5.5 software.Results Of the total 229 isolates of Enterobacter cloacae,59.0% was from respiratory specimens,13.5% from urine,and 12.7% from wound secretions/pus.The resistance rates of Enterobacter cloacae to meropenem,imipenem,and cefoperazone/sulbactam were 0.0%,0.4% and 2.5%,respectively,while to ampicillin,cefazolin and cefoxitin,the resistance rates were 98.7%,96.9% and 97.5%,respectively.Conclusion Enterobacter cloacae has multiple resistance with complex mechanisms.Reasonable use of antimicrobial drugs is important for reducing the emergence of resistant Enterobacter cloacae and its prevalence in the hospital.